Seagen Inc (SGEN)

NASDAQ
147.49
+2.78(+1.92%)
  • Volume:
    391,594
  • Bid/Ask:
    147.46/147.64
  • Day's Range:
    143.69 - 148.85

SGEN Overview

Prev. Close
144.71
Day's Range
143.69 - 148.85
Revenue
2.27B
Open
145.21
52 wk Range
133.2 - 213.85
EPS
3.6
Volume
391,594
Market Cap
26.68B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
1,054,819
P/E Ratio
40.17
Beta
0.86
1-Year Change
-8.32%
Shares Outstanding
181,477,076
Next Earnings Date
Jul 29, 2021
What is your sentiment on Seagen Inc?
or
Vote to see community's results!

Seagen Inc News

Seagen Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyBuyBuy
Technical IndicatorsSellSellStrong BuyStrong BuySell
SummaryNeutralNeutralStrong BuyStrong BuyNeutral

Seagen Inc Company Profile

Seagen Inc Company Profile

Employees
2092

Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA or tucatinib, for treatment of certain metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancers. The Company is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its pipeline includes ladiratuzumab vedotin, an antibody-drug conjugate (ADC) targeting LIV-1.

Read More
  • The European Commission (EC) has granted marketing authorization for Seagen's (NASDAQ:SGEN) Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
    0
    • What is the news?
      0
      • Apprently they may be included in the S&P 500, and hence funds. Just like Tesla a few weeks back
        1
      • Ludovic Raymond Did you hold a position?
        0
    • Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
      1
      • Price drop is the result of the #1 Institutional holder (Baker Bros) selling the entire position.
        0
        • You say Baker Bros sold the entire position, 27.5%. this is not possible. not that much volume.
          0
        • Executing through a secondary offering. The company issued a press release on it.
          0
      • Seagen (SGEN) Gets Positive CHMP Opinion for Breast Cancer Drug  December 14, 2020
        0
        • 180+
          0
          • Buy buy buy
            0
            • Reports tomorrow worth a BUY? > www.tradeticker.news/sgen/
              1
              • Phase 2 data of Tisotumab vedotin would be something to watch for !!! Eventual approval by FDA is anticipated
                0
                • It’s a great buy at $149.. Target $185
                  0
                  • Did you hold a position?
                    0
                • buy?
                  1
                  • Lots of pratying an thing the Lord an praising Him.an Represents of sin believe an truest in the Lord Jesus Christ an Father an the Holy spirit
                    5
                    • Think you all very much you don't a great job .be bless if it God will
                      3
                      • Powerful teaming up with Merck on cancer drug!
                        0
                        • i dont care sbout the stock but i am thankful for their work.
                          0
                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.